A new publication involving thymosin alpha-1 was released on May 28, 2026. The study, titled "A prospective clinical study on the effectiveness of Phellinus igniarius decoction in treating immune dysfunction in colorectal cancer patients following chemotherapy," appeared in the Journal of Traditional and Complementary Medicine.
Thymosin alpha-1 remains classified as an unapproved compound used in research contexts. The publication is listed under PubMed ID 42698582 and is available through the journal's indexed record.
No findings, outcomes, or efficacy data from the study are detailed here. This brief reports only that the publication exists, its title, its journal, and its publication date, as stated in the available event record.
Readers interested in background information on thymosin alpha-1, including its research status and general context, can consult the compound overview for more detail.